Objectives It remains an unsolved issue whether hormone replacement therapy (HRT) lowers blood pressure. This randomized trial examined the effect of 17â-oestradiol combined cyclically with gestodene on blood pressure of postmenopausal women who were not on antihypertensive medication. All subjects had an increased risk for adverse vascular events as indicated by intima± media thickness of carotid arteries and standard risk factors.
Introduction
Elevated blood pressure is a major risk factor for vascular disease mortality in women and blood pressure lowering substantially reduces this risk [1, 2] . In normotensive women who were postmenopausal for only few years, randomized controlled trials using 17â-oestradiol or oestradiol valerate, administered orally or transdermally, showed that long-term treatment lowered blood pressure [3±7] . In hypertensive women, short-term (24 h) treatment with 17â-oestradiol resulted in a small decrease of blood pressure [8, 9] , whereas long-term treatment (months) reduced target organ damage [10] but not blood pressure [10, 11] . Randomized studies using conjugated equine oestrogens consistenly found no effect on blood pressure in patients with coronary heart disease (CHD) [12] or with diabetes [13] , or in a large sample of apparently healthy women [14] . An effect of progestin on blood pressure was not observed [3,5,7,10±14] . It remains unsettled whether 17â-oestradiol lowers blood pressure in elder women with risk factors for vascular disease. Whereas in secondary prevention (i.e. for women with CHD) evidence is mounting that hormone replacement therapy (HRT) does not prevent disease progression or further cardiac events [15, 16] , HRT has been suggested as a primary prevention strategy for women at increased risk for CHD [17, 18] . Because the relationship between blood pressure and cardiovascular disease is graded, even in individuals with blood pressure within the normal range (, 130/85 mmHg) a lower (optimal) blood pressure (, 120/80 mmHg) is associated with a lower cardiovascular risk [19, 20] . Thus, we sought to clarify whether HRT alone, independently from antihypertensive medication, in¯uences blood pressure in women with high risk for vascular disease. Such risk is indicated by an increased intima±media thickness (IMT) in the carotid arteries [21, 22] .
The present randomized controlled trial examined the hypothesis that 17â-oestradiol combined with standard dose and with low dose gestodene would lower systolic blood pressure (SBP) and diastolic blood pressure (DBP) more than no HRT during a 48-week treatment period.
Methods

Subjects and design
The study was part of a larger trial (Postmenopausal HOrmone Replacement against Atherosclerosis, PHOREA) which has been reported in detail elsewhere [23] . This trial was randomized, controlled, observerblind and conducted in one university hospital outpatient centre, according to the International Conference for Harmonization Guidelines for Good Clinical Practice (ICH-GCP). The investigation aimed to examine the effect of two different HRT regimens on intermediate endpoints of atherosclerotic disease, and on risk factors for atherogenesis. Subjects were randomized into three groups: The HRT group with standard-dose progestin ( HRT 1) received tablets containing 1 mg of 17â-oestradiol per day continuously, with addition of 0.025 mg gestodene on days 17±28 of each 4-week cycle. The HRT group with low-dose progestin (HRT 2) received the same dose of oestrogen, but gestodene was added in each third cycle only. The no HRT group received no oestrogen or progestin, also excluding topical application. The duration of treatment was 48 weeks (12 cycles).
The study population consisted of a sample of postmenopausal women who were invited to participate by means of local media. To be eligible in the main study, a woman had to be postmenopausal (last regular bleeding or surgical menopause more than 1 year previously or, in case of hysterectomy, follicle stimulating hormone levels . 40 IU/l), and to be aged between 40 and 70 years. An IMT of more than 1 mm in at least one of the prede®ned segments of the carotid arteries as detected by high-resolution ultrasound was required. This cut-off was chosen since the hazard ratio for women with a carotid artery mean maximum IMT of > 1 mm had been demonstrated to be 5.07 for CHD incidence compared to those with IMT , 1 mm [21] .
Those subjects excluded from the study were women with a history of endometrial hyperplasia or cancer unless hysterectomized, any other malignant disease, severe climacteric complaints or other conditions requiring HRT, serious complaints during previous use of hormones, myocardial infarction within the last 6 months or CHD that required treatment for angina, history of thrombophlebitis or thromboembolic disorder, history of ischaemic cerebrovascular disease, blood pressure greater than 200/110 mmHg after 5-min rest, thyroid disorder unless controlled and stable on treatment for more than 1 year, major depression, or any other serious illness.
Furthermore for the present study, subjects were excluded if they were on antihypertensive medication at study start or if commencement of antihypertensive treatment was planned at randomization. Subjects who started antihypertensive medication during the treatment period were excluded from the analysis since decisions concerning indication and form of antihypertensive treatment were up to the subjects' personal physicians. Therefore, blood pressure in these subjects was expected to change considerably and independently from the effect of the study medication. All subjects gave their informed consent. The study was approved by the local ethics committee of the faculty of medicine of the University of Munich.
Subjects were seen as outpatients at study start, and at weeks 12, 22 and 48. At week 12 and 48, women took the combined 17â-oestradiol plus gestodene treatment, at week 22, they took 17â-oestradiol only. At each visit, history was taken and a physical examination was performed including blood pressure measurements and an extensive laboratory work-up. General health advice, advice for treatment of hypertension and elevated low density lipoprotein cholesterol followed the guidelines of the American Heart Association [24] . The study medication was dispensed at each visit and all blisters and all remaining tablets were collected during subsequent visits. Compliance with medication was assessed by follicle stimulating hormone measurement, pill count and daily documentation of study drug intake and of vaginal bleeding in a diary kept by the subject. The intention-to-treat population was de®ned as all randomized subjects who did not take antihypertensive medication during the study. The valid-case population was de®ned as all intention-to-treat subjects who in addition did not violate any eligibility criteria at randomization or during the study, took at least 91.7% (11 cycles) of the study medication and did not use any additional HRT preparations (including topical application) during the trial.
Measurements
Blood pressure was measured in accordance with the recommendations of the Sixth Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure, JNC VI [19] . All follow-up examinations took place approximately (within 2 h) at the same time of day as the baseline measurement. Subjects were told to refrain from ingestion of caffeine and from smoking on the day of the respective visit. All measure-ments were performed in the same arm; if the blood pressure differed more than 5 mmHg between left and right arm, the arm with the higher blood pressure was chosen. After subjects had rested in recumbent position for 5 min, blood pressure was measured automatically, three times separated by 2 min, by an electronic device (Dinamap, Johnson and Johnson Medical Inc., Arlington, Texas, USA), using the appropriate cuff size. The readings were averaged. If two readings differed by more than 5 mmHg, additional measurements were obtained. All measurements [i.e. SBP, DPB, mean arterial blood pressure (MAP) and heart rate] were documented immediately, as read from the display of the device. All further steps of data handling up to the closing of the electronic ®le were carried out by an independent clinical research organization and the personnel was blinded with respect to treatment allocation.
IMT of the carotid arteries was measured by highresolution duplex ultrasound according to a standardized protocol, described elsewhere [23] . In brief, images of the maximum IMT of the far wall of the common and internal carotid artery and the carotid bulb on both sides were recorded at study start and study end, and were measured by blinded personnel after study end from the digitized images. High density lipoprotein cholesterol, blood glucose, follicle stimulating hormone and thyroid stimulating hormone were measured by routine laboratory methods. Low-density lipoprotein cholesterol was calculated according to the Friedewald formula [25] . Physical activity was de®ned as at least moderate-intensity dynamic exercise on a regular basis. Subjects were categorized according to the JNC VI classi®cation (optimal, normal, high-normal, hypertensive stage 1, 2 or 3 blood pressure) by their SPB and DBP at baseline [19] .
Statistical analysis
For data analysis, SPSS 10.0.7 for Windows (SPSS, Chicago, Illinois, USA) was used. Gaussian distribution was tested by the Kolmogorov±Smirnov±Lilliefors test. Homogeneity of variances was assessed by Levene9s test. The effect of each of the two HRT treatment arms compared to control on the primary outcome measures (change of SBP, DBP, MAP and pulse pressure during follow-up) was tested by the General Linear Model procedure with change of blood pressure from baseline to timepoint (12 weeks, 22 weeks, 48 weeks) as dependent variables, group as factor and baseline value as covariate. In this hierachical procedure, the`multivariate' P-value indicates the probability of an error if accepting any difference of the changes during the study accross the groups. All other P-values for between-group comparisons at distinct points of time are thus corrected for multiple testing by the same testing procedure.
An additional model was built with change of haemoglobin and with smoking status at 48 weeks as covariate. For exploratory analyses of other baseline characteristics and of changes of other variables during follow-up, differences between HRT 1 and no HRT and HRT 2 and no HRT were examined by one-way ANOVA or chi-squared test, according to the nature of the data.
Results
Randomization of the 226 eligible subjects into three groups resulted in an even distribution of all measured characteristics relevant to arterial blood pressure. During follow-up, 29 subjects (four subjects in HRT 1, 12 in HRT 2 and 13 in no HRT; P 0.013 for HRT 1 versus no HRT; P 0.885 for HRT 2 versus no HRT) were started on antihypertensive medication either following the advice of the investigators or the decision of the subject's personal physician. These subjects were primarily excluded from analysis, resulting in an intention-to-treat sample of 197 subjects. Their baseline characteristics are given in Table 1 .
The change of blood pressure of the excluded subjects taking antihypertensive medication was not signi®-cantly different between treatment groups at any time during follow-up. Another 30 subjects ended participation prematurely: in the HRT 1 group, six subjects experienced typical side-effects of HRT, ®ve withdrew for other personal reasons, two were excluded because of later emergence of an exclusion criterion. In the HRT 2 group, reasons for stopping were side-effects in four subjects and personal reasons in seven subjects. Side-effects in the HRT groups were mastalgia, abdominal pain, headache, weight gain, nausea and undesirable vaginal bleeding as reported previously in greater detail [23] . In the no HRT group, the reason for stopping was vasomotor symptoms in two subjects, personal reasons in three subjects and not being postmenopausal in one subject. Blood pressure measurements were completed in 167 subjects (intention-totreat) and 129 subjects (valid-case analysis), respectively.
DBP decreased most in the HRT 2 group, the change being signi®cantly different from the change in the no HRT group at 22 and 48 weeks ( Table 2 , Fig. 1 ). The decrease of DBP in the HRT 1 group was smaller than in the HRT 2 group but still signi®cantly greater than the change in the no HRT group at 48 weeks ( Table 2 , Fig. 1 ). This resulted in a signi®cant decrease of MAP in the HRT 2 group compared to the no HRT group at weeks 22 and 48 (Table 2 ). For SBP, the same tendency was observed with the greatest decrease in the HRT 2 group, but the difference did not reach signi®cance (Table 2) . Pulse pressure decreased in all groups but signi®cantly more in the no HRT group than in the HRT groups (Table 2) . In all groups, there was a strong and signi®cant inverse correlation between DBP at beginning and the change of DBP during follow-up (i.e. the higher the DBP was at beginning, the greater the decrease).
After exclusion of subjects who were not fully compliant with the medication (valid-case analysis) the difference in decrease of DBP and of MAP in the HRT 2 group compared to the no HRT group became more pronounced and was signi®cant throughout the followup (beginning at week 12). The decrease of DBP and MAP in the HRT 1 group again was smaller than in the HRT 2 group, and greater than in the no HRT group (data not shown).
According to the JNC VI classi®cation, 43.1% of the subjects improved by < 1 category, 41.3% remained unchanged and 15.6% worsened by > 1 category. Although more subjects (47.6 and 46.9% in the HRT 1 and HRT 2 group, respectively) improved compared to 34.5% in the no HRT group, this variation of change was not signi®cant.
Baseline values and change during follow-up of other variables potentially related to arterial blood pressure HRT 1 indicates hormone replacement therapy with 17â-oestradiol and standard dose gestodene, HRT 2 indicates 17â-oestradiol and lowdose gestodene, no HRT indicates the control group. Intention-to-treat population. P-values for comparison between HRT 1 and no HRT, and HRT 2 and no HRT. with low progestin, but increased by 1.0 mmHg in women without HRT after 48 weeks. SBP decreased in all groups but the change was not signi®cantly different accross groups. This result of the intention-to-treat analysis was corroborated by the valid-case analysis.
Controlling for other variables that varied signi®cantly by group during treatment (haemoglobin and smoking status) did not change the results.
A meta-analysis of randomized drug treatment trials estimated that a decrease of 6 mmHg in DBP would reduce the overall mortality from vascular disease by 21%, fatal and non-fatal stroke by 42% and fatal and non-fatal CHD by 14% in women with mild to moderate hypertension [26] . Thus, the reduction in DBP in our study may translate into a reduction of vascular events, even if the observed antihypertensive effect is limited to otherwise untreated women with normal or high normal blood pressure [19] .
Epidemiological observations from the Framingham study indicate that at any given systolic pressure > 120 mmHg, there was an inverse relation between DBP and CHD events, and pulse pressure was the best predictor of cardiovascular events [27] . In our study, at 48 weeks, pulse pressure was diminished in all groups which suggests a risk reduction. Interestingly, the decrease in pulse pressure was signi®cantly greater in the no HRT group than in the HRT groups. It is unknown whether reduced pulse pressure or reduced DBP reduces risk more profoundly [28] . One mechanism suggested to explain the potential harm of a low DBP is a reduced coronary blood¯ow in diastole, especially in patients with CHD where coronary¯ow is impaired by stenoses [28, 29] . In women without CHD, the situation is less clear. Previously, we demonstrated in a larger trial, which was conducted largely with the same population as the present trial, that neither HRT 1 nor HRT 2 slowed progression of atherosclerosis in carotid arteries [23] . Conversely, lowering of blood pressure is not necessarily accompanied by a slowed progression of carotid atherosclerosis [30] . Thus, the antihypertensive action of 17â-oestradiol may be an independent vasoprotective mechanism. HRT for all healthy women with cardiovascular risk factors is currently advocated by some but not all experts in the ®eld [18] . Recently, other HRT regimens, such as the one studied here, have been developed that may have a better ratio of risk and bene®t. This remains to be determined in trials such as ours, before large scale clinical trials can be carried out.
DBP but not SBP was signi®cantly lowered by HRT in the present trial. Several other studies demonstrated that only DBP was lowered [3, 9] , that DBP was lowered earlier in the course of treatment than SBP [5] or that DBP was lowered in a broader range of measurement situations [6] . Elevated SBP is largely due to age-related stiffening of central elastic arteries [28] . We recently demonstrated in a randomized trial that longterm HRT does not improve stiffness of these arteries [31] whereas previous epidemiological studies indicated a reduction of stiffness [32, 33] . Several mechanisms have been proposed for an effect of oestrogen on blood pressure. Oestrogen increases the production of angiotensinogen by the liver which in turn prompts a feedback mechanism by which renin secretion and plasma renin activity are suppressed [34, 35] . HRT seems to act as an angiotensin converting enzyme inhibitor [36] . However, in the clinical situation, the renin±angioten-sin±aldosterone system seems not to mediate the effect of HRT on blood pressure [3, 6, 7, 11] . There is some evidence that oestrogen given in higher doses than in the present study reduces sympathetic neural activity; this was indicated by a decreased heart rate [6] and an attenuated vasoconstriction in response to norepinephrine and less total body norepinephrine spillover [4] . In our study, heart rate did not change with HRT. Eventually, oestrogen promotes vasodilation by increased bioavailability of nitric oxide [37] which also may account for a lowering of blood pressure.
In the present study, HRT with low-dose progestin (i.e. every third month only) showed a somewhat stronger effect on blood pressure than HRT with standard dose (i.e.. every month). This was surprising since, to our knowledge, all randomized trials that compared HRT with and without progestin did not ®nd any difference in the effect on blood pressure [3, 7, 11, 14, 38] . Due to their antimineralocorticoid properties, progestins are expected to lower blood pressure [34] . Gestodene in particular has aldosterone-antagonistic effects; when used as an oral contraceptive (high dose), blood pressure remained stable or even decreased [39] . In accordance with this observation, blood pressure was even slightly lower at week 12 when all women on HRT took the combination of 17â-oestradiol plus gestodene than at week 22 when all took 17â-oestradiol only. Furthermore, signi®cantly less subjects who were initially randomized to HRT 1 were started on antihypertensive medication by their personal physicians and consequently excluded from the primary analysis. Thus, taking into account the small, nonsigni®cantly different effect between both HRT groups on DBP (Fig. 1) , the superiority of low-dose gestodene HRT over standard dose might well be a chance ®nding.
The dip in SBP and DBP which occurred in all groups in week 12 compared to study start and to week 22 may in part be explained by increasing adaptation to the study situation and by a short-term effect of general health advice (more physical activity, low fat, low calories, less salt). A similar effect had been observed in the Postmenopausal Oestrogen/Progestin Interventions Trial [14] . The more pronounced and sustained blood pressure drop in the HRT groups can be interpreted as a combination of the effect described above, and the synergistic effects of 17â-oestradiol and gestodene at week 12.
Interestingly, studies using conjugated equine oestrogens in the HRT regimens did not demonstrate a bene®cial effect on blood pressure [12±14] . Most of the experimental and mechanistic studies showing potentially vasoprotective effects of oestrogen were performed with 17â-oestradiol [37] . Thus, it may be speculated that 17â-oestradiol and conjugated equine oestrogens differ in their effect on vascular diseases.
The exclusion of women who were treated with antihypertensive drugs represents both a strength and a limitation of the present study. Trials that examined long-term HRT and involved hypertensive subjects on antihypertensive medication failed to demonstrate an additional effect on blood pressure [10, 12] . Given the potent action of antihypertensives which were predominantly used in combination [10, 12] , the potentially small additional effect of HRT may have been masked due to the lack of statistical power. An alternative explanation may be that oestrogen shares mechanisms of action with â-blockers, angiotensin converting enzyme inhibitors, some diuretics, and calcium channel blockers [40] , and that the effect of the respective drug may be not signi®cantly enhanced by oestrogen. The exclusion of subjects who were started on antihypertensive medication may have lead to an exclusion of women whose blood pressure would have risen instead of fallen in reaction to HRT. Since the number of subjects on new hypertensive medication was signi®-cantly smaller in HRT 1 and similar in HRT 2 compared to no HRT, this assumption is very unlikely. Further limitations of this trial include the lack of blinding towards treatment allocation. Blood pressure was measured by a semi-automatic device thus reducing the in¯uence of the physician who performed the measurements to a minimum. All further steps of data handling were carried out by blinded personnel who were not in contact with the study subjects. Furthermore, this study did not measure ambulatory blood pressure, which is a means of decreasing measurement variability and increase statistical power. However, the power of this study was suf®cient to detect the decrease of diastolic of®ce blood pressure. A decrease of SBP, as demonstrated in other studies [5±7], may thus have been missed.
In conclusion, postmenopausal women who were at increased risk for future vascular disease, as indicated by increased IMT in the carotid arteries, elevated blood pressure and other risk factors, were studied in this randomized trial. HRT with 17â-oestradiol and gestodene in two regimens for 48 weeks signi®cantly lowered DBP compared to no HRT. The relative importance of this ®nding remains to be established in a trial designed to study the effects of 17â-oestradiol on clinical endpoints.
